Trial Profile
A Phase III, Randomized, Two-armed, Parallel, Double-blind, Active-controlled, Non-inferiority Clinical Trial to Determine the Non-inferior Therapeutic Efficacy and Safety Between Arylia (60 mg, Denosumab, Produced by AryoGen Pharmed) Compared With Prolia (60 mg, Denosumab, the Reference Drug, Produced by Amgen Company) in the Improvement of Bone Mineral Densitometry (BMD) Among Osteoporotic Postmenopausal Women
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 07 Jul 2022
Price :
$35
*
At a glance
- Drugs Denosumab (Primary)
- Indications Postmenopausal osteoporosis
- Focus Registrational; Therapeutic Use
- Sponsors AryoGen Pharmed
- 30 Jun 2022 Primary endpoint (Percentage change in BMD at the lumbar spine (L1-L4), femoral neck, and total hip) has been met as per results published in the Arthritis Research and Therapy
- 30 Jun 2022 Results published in the Arthritis Research and Therapy
- 08 Jul 2020 Status changed from recruiting to active, no longer recruiting.